Hayashida S, Gutiérrez L, Luna VJ, Osnaya F, Sumano H

Idioma: Español/Inglés
Referencias bibliográficas: 28
Paginas: 197-205
Archivo PDF: 155.14 Kb.

RESUMEN

El objetivo de este trabajo fue determinar la bioequivalencia entre dos preparados comerciales de amoxicilina-ácido clavulánico disponibles en forma de tableta para uso oral en perros, y cuyo intervalo de dosificación indicado por los fabricantes es de 12 horas. Se calculó el perfil farmacocinético de cada preparado, a una dosis oral de 12.5 mg/kg de amoxicilina y ácido clavulánico en doce perros adultos mediante un modelo cruzado. Se determinó la concentración activa de la combinación de ambos fármacos en cada muestra de plasma, utilizando un método de análisis microbiológico por difusión en agar. El cálculo farmacocinético se llevó a cabo con un modelo no compartamental y los valores obtenidos se analizaron mediante un ANDEVA y prueba T de Bonferroni, con una P ‹ 0.05. Tomando en cuenta las pautas internacionales, la formulación genérica resultó no ser bioequivalente a la de referencia. Esto es, se obtuvieron valores de AUC0-∞ 9.08 ± 0.26 μg h/ml y Cmax 5.48 ± 0.19 μg/ml para el genérico vs AUC0-∞ 13.28 ± 0. 30 μg h/ml y Cmax 2.9 ± 0.17 μg/ml para el de referencia. Si se considera un punto de inflexión para bacterias susceptibles, de 0.25 μg/ml, el preparado genérico requiere un intervalo de dosificación de ocho horas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. FRANCIS ME, MARSHALL AB, TURNER WT. Amoxicillin: clinical trials in dogs and cats. Vet Rec 1978; 102: 377-380.

2. RICHMOND MH, SYKES RB. The ß-lactamases of gram-negative bacteria and their possible physiologic role. In: ROSE AH, TEMPEST DW, editors. Advances in Microbial physiology. Vol 9. London: Academic Press, 1973: 31-38.

3. BROWN AG, BUTTERWORTH D, COLE M, HANSCOMB G, HOOD JD, READING C et al. Naturally- occurring ß lactamase inhibitors with antibacterial activity. J Antibiot 1976; 29: 668-669.

4. READING C, COLE M. Clavulanic acid: A ß-lactamaseinhibiting ß-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11: 852-857.

5. KAYE CM, ALLEN A, PERRY S, MCDONAGH M, DAVY M, STORM K et al. The Clinical Pharmacokinetics of a new pharmacokinetically enhaced formulation of amoxicillin/ clavulanate. Clin Ther 2001; 23: 578-584.

6. BYWATER RJ, PALMER GH, BUSWELL JF, STANTON A. Clavulanate- potentiated amoxicillin: Activity in vitro and bioavailability in the dog. Vet Rec 1985; 116: 33-36.

7. VREE TB, DAMMERS E, VAN DUURE E. Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin™ and Synulox™ in healthy dogs. J Vet Pharmacol Ther 2003; 26: 165-171.

8. KERC J, OPARA J. A new amoxicillin/clavulanate therapeutic system: Preparation, in vitro and pharmacokinetic evaluation. Int J Pharm 2007; 335: 106-113.

9. BARR WH, ZOLA EM, CANDLER EL, HWANG SM, TENDOLKAR AV, SHAMBUREK R et al. Differential absorption of amoxicillin from the human small and large intestine. Clin Pharmacol Ther 1994; 56: 279-285.

10. OGATA H, AOYAGI N. Bioavailability of nalidixic acid from uncoated tablets in humans and in vitro dissolution rates. Int J Clin Pharmacol Toxicol Ther 1984; 22: 240-245.

11. LUI CY, AMIDON GM, BERARDI RR, FLEISHER D, YOUNGBERG C. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dogs as a model for oral absorption in humans. J Pharm Sci 1986; 75: 271-274.

12. BENNETT JV, BRODIE JL, BRENNER EJ, KIRBY J. Simplified accurate method for antibiotic assay of clinical specimens. Appl Microbiol 1966; 14: 170 – 177.

13. EUROPEAN MEDICINES AGENCY. Committee for veterinary medicinal products: Guidelines for the Conduct of Bioequivalence studies for Veterinary Medicinal Products. London: EMA, 2001.

14. RIVIERE JE. Unique problems associated with the determination of veterinary drug preparation bioequivalence. J Vet Pharmacol Ther 1994; 17: 86-88.

15. STEINIJANS V, HAUSCHKE D, JONKMAN G. Controversies in bioequivalence studies. Clin Pharmacokinet 1992; 22: 247-253.

16. CRAIG WA. Pharmacokinetic/Pharmacodynamic parameters: Rationale for Antibacterial Dosing of mice and men. Clin Infect Dis 1998; 26:1-12.

17. ARANCIBIA A, GUTTMANN J, GONZALEZ G, GONZALEZ C. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother 1980; 17: 199–202.

18. MARIER JF, BEAUDRY F, DUCHARME MP, FORTIN D, MOREAU JP, MASSÉ R et al. A pharmacokinetic study of amoxicillin in febrile beagle dogs following repeated administrations of endotoxin. J Vet Pharmacol Ther 2001; 24: 379-383.

19. ZIA H, SHALCHIAN N, BORHANIAN F. Kinetics of amoxicillin degradation in aqueous solution. Can J Pharmacol Sci 1977; 12:80-83.

20. WESTPHAL JF, DESLANDES A, BROGARD JM, CARBON C. Reappraisal of amoxicillin absorption kinetics. J Antimicrob Chemother 1991; 27:647-654.

21. LI M, ANDERSON GD, PHILLIPS BR, KONG W, SHEN DD, WANG J. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos 2006; 34: 547-555.

22. WEITSCHIES W, FRIEDRICH C, WEDEMEYER RS, SCHMIDTMANN M, KOSCH O, KINZIG M et al. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur J Pharm Biopharm 2008; 2:641-648.

23. CLINICAL AND LABORATORY STANDARDS INSTITUTE. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals. Approved Standard. 2nd ed. Wayne PA: NCCLS document M31-A, 2004.

24. GANIERE JP, MEDAILLE C, MANGION C. Antimicrobial Drug susceptibility of Staphylococcus intermedius Clinical Isolates from canine Pyoderma. J Vet Med 2005; 52: 25-31.

25. PAPICH MC. Susceptibility testing in animals- How breakpoints are derived and interpretation of susceptibility data. Proceeding of 15th AAVPT Biennial Symposium; 2007 May 20-24; Pacific Grove, California. [Serial online: 2007 May] [Cited: 2010 December 13]. Available from: http://www.ivis.org/proceedings/aavpt/2007/papich.pdf

26. ROY J, MESSIER S, LABRECQUE O, COX WR. Clinical and in vitro efficacy of amoxicillin against bacteria associated with feline skin wounds and abscesses. Can Vet J 2007; 48: 607-611.

27. GOODMAN LS, GILMAN A. The Pharmacological basis of Therapeutics. 2nd ed. New York: Macmillan, 1956.

28. AMBROSE PGJ, OWENS RC, GRASELA D. Antimicrobial pharmacodynamics. Med Clin North Am 2000; 84: 1431-1446.